4P-Pharma received the Seal of Excellence from the European Commission for its application related to the development of a disease modifier treatment for osteoarthritis, 4P-004 to the Horizon 2020 EIC Accelerator (SME instrument).
Following evaluation by an international panel of independent experts, 4P-Pharma’s project was scored as a high-quality proposal in this highly competitive evaluation process, passing all their stringent assessment thresholds for the 3 award criteria (i.e. excellence, impact and implementation).
A poster on 4P-004 entitled “Protective Effects Of Intra-Articular Formulated Liraglutide In Osteoarthritis” (#1970) will be presented during the 2nd Therapeutic Discoveries from Bench to First in Human Clinical Trials Conference, in Riyadh, Saudi Arabia, February 25th -27th, 2020.
Revital Rattenbach, CEO de 4P-Pharma, sera l’ambassadrice du Deeptech tour organisé par Bpifrance au Centre International de Conférences de Sorbonne Université à Paris le 9 mars 2020.
Elle interviendra lors de la session plénière en tant qu’entrepreneur de l’écosystème.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
4P-Pharma received the Seal of Excellence from the European Commission
4P-Pharma received the Seal of Excellence from the European Commission for its application related to the development of a disease modifier treatment for osteoarthritis, 4P-004 to the Horizon 2020 EIC Accelerator (SME instrument).
Following evaluation by an international panel of independent experts, 4P-Pharma’s project was scored as a high-quality proposal in this highly competitive evaluation process, passing all their stringent assessment thresholds for the 3 award criteria (i.e. excellence, impact and implementation).
4P-Pharma will present 4P-004 at the 2nd Therapeutic Discoveries Conference in Riyadh, Saudi Arabia
A poster on 4P-004 entitled “Protective Effects Of Intra-Articular Formulated Liraglutide In Osteoarthritis” (#1970) will be presented during the 2nd Therapeutic Discoveries from Bench to First in Human Clinical Trials Conference, in Riyadh, Saudi Arabia, February 25th -27th, 2020.
4P-Pharma au Deeptech tour de Bpifrance à Paris-Sorbonne Université
Revital Rattenbach, CEO de 4P-Pharma, sera l’ambassadrice du Deeptech tour organisé par Bpifrance au Centre International de Conférences de Sorbonne Université à Paris le 9 mars 2020.
Elle interviendra lors de la session plénière en tant qu’entrepreneur de l’écosystème.
Lien de l’évènement et programme : http://deeptechtoursorbonne.evenium-site.com/site/le-deeptech-tour-sorbonne-universite;jsessionid=UE6Dr4FnVKg!bwsMI8rdesYe.gl2
4P-Pharma at Biotech Showcase 2020
4P-Pharma’s CEO, Revital Rattenbach, will attend the upcoming Biotech Showcase 2020 in San Francisco (USA), January 13th-15th, 2020.
Contact us via the partnering platform or by e-mail to schedule a meeting and discuss future collaborations.
Happy New Year 2020 !
4P-Pharma team wishes you a Happy New Year to you and your loved ones!